{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:59:48Z","timestamp":1793667588201,"version":"4.5.1"},"reference-count":100,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T00:00:00Z","timestamp":1541721600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Substantial improvements in survival have been seen in multiple myeloma (MM) over recent years, associated with the introduction and widespread use of multiple novel agents and regimens, as well as the emerging treatment paradigm of continuous or long-term therapy. However, these therapies and approaches may have limitations in the community setting, associated with toxicity burden, patient burden, and other factors including cost. Consequently, despite improvements in efficacy in the rigorously controlled clinical trials setting, the same results are not always achieved in real-world practice. Furthermore, the large number of different treatment options and regimens under investigation in various MM settings precludes the feasibility of obtaining head-to-head clinical trial data, and there is a temptation to use cross-trial comparisons to evaluate data across regimens. However, multiple aspects, including patient-related, disease-related, and treatment-related factors, can influence clinical trial outcomes and lead to differences between studies that may confound direct comparisons between data. In this review, we explore the various factors requiring attention when evaluating clinical trial data across available agents\/regimens, as well as other considerations that may impact the translation of these findings into everyday MM management. We also investigate discrepancies between clinical trial efficacy and real-world effectiveness through a literature review of non-clinical trial data in relapsed\/refractory MM on novel agent\u2212based regimens and evaluate these data in the context of phase 3 trial results for recently approved and commonly used regimens. We thereby demonstrate the complexity of interpreting data across clinical studies in MM, as well as between clinical studies and routine-care analyses, with the aim to help clinicians consider all the necessary issues when tailoring individual patients\u2019 treatment approaches.<\/jats:p>","DOI":"10.1038\/s41408-018-0141-0","type":"journal-article","created":{"date-parts":[[2018,11,9]],"date-time":"2018-11-09T04:49:05Z","timestamp":1541738945000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":225,"title":["Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting"],"prefix":"10.1038","volume":"8","author":[{"given":"Paul G.","family":"Richardson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus F.","family":"San Miguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Hajek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1763-6609","authenticated-orcid":false,"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarina","family":"Luptakova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Romanus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Skacel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth C.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,11,9]]},"reference":[{"key":"141_CR1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar, S. K. et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28, 1122\u20131128 (2014).","journal-title":"Leukemia"},{"key":"141_CR2","unstructured":"National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Myeloma. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html: (National Cancer Institute, 2017)."},{"key":"141_CR3","unstructured":"Howlader, N. et al. SEER Cancer Statistics Review, 1975\u20132014, https:\/\/seer.cancer.gov\/csr\/1975_2014\/. Table 18.9, Myeloma, SEER Relative Survival (Percent) By Year of Diagnosis, All Races, Males and Females 2017. https:\/\/seer.cancer.gov\/csr\/1975_2014\/browse_csr.php?sectionSEL=18&pageSEL=sect_18_table.09.html; (National Cancer Institute, Bethesda, 2017)."},{"key":"141_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.6004\/jnccn.2017.0023","volume":"15","author":"SK Kumar","year":"2017","unstructured":"Kumar, S. K. et al. Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J. Natl Compr. Canc. Netw. 15, 230\u2013269 (2017).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"141_CR5","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1586\/17474086.2015.1001360","volume":"8","author":"T Guglielmelli","year":"2015","unstructured":"Guglielmelli, T. & Palumbo, A. Multiple myeloma: is a shift toward continuous therapy needed to move forward? Expert Rev. Hematol. 8, 253\u2013256 (2015).","journal-title":"Expert Rev. Hematol."},{"key":"141_CR6","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. J. Clin. Oncol. 33, 3459\u20133466 (2015).","journal-title":"J. Clin. Oncol."},{"key":"141_CR7","doi-asserted-by":"publisher","first-page":"2435","DOI":"10.1038\/leu.2017.111","volume":"31","author":"NJ Bahlis","year":"2017","unstructured":"Bahlis, N. J. et al. Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial. Leukemia 31, 2435\u20132442 (2017).","journal-title":"Leukemia"},{"key":"141_CR8","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy, P. L. et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J. Clin. Oncol. 35, 3279\u20133289 (2017).","journal-title":"J. Clin. Oncol."},{"key":"141_CR9","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker, L. et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N. Engl. J. Med. 371, 906\u2013917 (2014).","journal-title":"N. Engl. J. Med."},{"key":"141_CR10","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s00520-015-2644-6","volume":"23","author":"R Baz","year":"2015","unstructured":"Baz, R. et al. Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support. Care Cancer 23, 2789\u20132797 (2015).","journal-title":"Support. Care Cancer"},{"key":"141_CR11","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1182\/blood-2016-09-692947","volume":"128","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar, S. V. & Harousseau, J. L. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood 128, 2757\u20132764 (2016).","journal-title":"Blood"},{"key":"141_CR12","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","volume":"35","author":"ES Kim","year":"2017","unstructured":"Kim, E. S. et al. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J. Clin. Oncol. 35, 3737\u20133744 (2017).","journal-title":"J. Clin. Oncol."},{"key":"141_CR13","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","volume":"35","author":"CHY van Beurden-Tan","year":"2017","unstructured":"van Beurden-Tan, C. H. Y., Franken, M. G., Blommestein, H. M., Uyl-de Groot, C. A. & Sonneveld, P. Systematic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and\/or Refractory Multiple Myeloma. J. Clin. Oncol. 35, 1312\u20131319 (2017).","journal-title":"J. Clin. Oncol."},{"key":"141_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-79","volume":"9","author":"T Li","year":"2011","unstructured":"Li, T., Puhan, M. A., Vedula, S. S., Singh, S. & Dickersin, K., Ad Hoc Network Meta-analysis Methods Meeting Working G. Network meta-analysis-highly attractive but more methodological research is needed. BMC Med. 9, 79 (2011).","journal-title":"BMC Med."},{"key":"141_CR15","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 375, 1319\u20131331 (2016).","journal-title":"N. Engl. J. Med."},{"key":"141_CR16","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A. et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 375, 754\u2013766 (2016).","journal-title":"N. Engl. J. Med."},{"key":"141_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S. et al. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N. Engl. J. Med. 373, 621\u2013631 (2015).","journal-title":"N. Engl. J. Med."},{"key":"141_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 17, 27\u201338 (2016).","journal-title":"Lancet Oncol."},{"key":"141_CR19","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372, 142\u2013152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"141_CR20","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P. et al. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 374, 1621\u20131634 (2016).","journal-title":"N. Engl. J. Med."},{"key":"141_CR21","doi-asserted-by":"publisher","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","volume":"3","author":"JF San-Miguel","year":"2016","unstructured":"San-Miguel, J. F. et al. Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. Lancet Haematol. 3, e506\u2013e515 (2016).","journal-title":"Lancet Haematol."},{"key":"141_CR22","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel, J. F. et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 15, 1195\u20131206 (2014).","journal-title":"Lancet Oncol."},{"key":"141_CR23","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/j.clml.2017.03.147","volume":"17","author":"D Romanus","year":"2017","unstructured":"Romanus, D. et al. Association Between Treatment Regimen Type in Second-Line Therapy (2LT) and Duration of Therapy (DOT) & Time To Next Treatment (TTNT) in a United States (US) Relapsed\/Refractory Multiple Myeloma (RRMM) Cohort. Clin. Lymphoma Myeloma Leuk. 17, e81\u2013e82 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"141_CR24","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17474086.2016.1195254","volume":"9","author":"S Jagannath","year":"2016","unstructured":"Jagannath, S. et al. Real-world treatment patterns and associated progression-free survival in relapsed\/refractory multiple myeloma among US community oncology practices. Expert Rev. Hematol. 9, 707\u2013717 (2016).","journal-title":"Expert Rev. Hematol."},{"issue":"s2","key":"141_CR25","first-page":"804","volume":"102","author":"C Cerchione","year":"2017","unstructured":"Cerchione, C. et al. Carfilzomib-lenalidomide-dexamethasone in the management of relapsed and refractory multiple myeloma: a real-life experience. Haematologica 102(s2), 804 (2017).","journal-title":"Haematologica"},{"issue":"s2","key":"141_CR26","first-page":"786","volume":"102","author":"M Ziff","year":"2017","unstructured":"Ziff, M. et al. Real world use of ixazomib with lenalidomide and dexamethasone for patients with relapsed and relapsed refractory multiple myeloma. Haematologica 102(s2), 786\u2013787 (2017).","journal-title":"Haematologica"},{"issue":"suppl","key":"141_CR27","doi-asserted-by":"publisher","first-page":"8038","DOI":"10.1200\/JCO.2017.35.15_suppl.8038","volume":"35","author":"A Lakshman","year":"2017","unstructured":"Lakshman, A. et al. Daratumumab-based combination therapies (DCT) in heavily-pretreated patients (pts) with relapsed and\/or refractory multiple myeloma (RRMM). J. Clin. Oncol. 35(suppl), 8038 (2017).","journal-title":"J. Clin. Oncol."},{"key":"141_CR28","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1182\/blood.V128.22.4516.4516","volume":"128","author":"A Branca","year":"2016","unstructured":"Branca, A. et al. Daratumumab Single Agent and Daratumumab Plus Pomalidomide and Dexametasone in Relapsed\/Refractory Multiple Myeloma: A Real Life Retrospective Evaluation. Blood 128, 4516 (2016).","journal-title":"Blood"},{"issue":"suppl","key":"141_CR29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.e19522","volume":"35","author":"N Biran","year":"2017","unstructured":"Biran, N. et al. Real-world outcomes with panobinostat in patients with penta- and quad-refractory multiple myeloma. J. Clin. Oncol. 35(suppl), e19522 (2017).","journal-title":"J. Clin. Oncol."},{"key":"141_CR30","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/j.clml.2017.03.217","volume":"17","author":"MA Baertsch","year":"2017","unstructured":"Baertsch, M. A. et al. Efficacy and Tolerability of the Histone-Deacetylase Inhibitor Panobinostat in Clinical Practice. Clin. Lymphoma Myeloma Leuk. 17, e119\u2013e120 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"141_CR31","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael, J. R. et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin. Proc. 88, 360\u2013376 (2013).","journal-title":"Mayo Clin. Proc."},{"key":"141_CR32","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J. Clin. Oncol. 33, 2863\u20132869 (2015).","journal-title":"J. Clin. Oncol."},{"key":"141_CR33","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clml.2017.06.013","volume":"17","author":"JJ Shah","year":"2017","unstructured":"Shah, J. J. et al. Analysis of Common Eligibility Criteria of Randomized Controlled Trials in Newly Diagnosed Multiple Myeloma Patients and Extrapolating Outcomes. Clin. Lymphoma Myeloma Leuk. 17, 575\u2013583 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"141_CR34","doi-asserted-by":"crossref","unstructured":"Kim E. S., et al. Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement. J. Clin. Oncol. JCO2017737916 (2017).","DOI":"10.1200\/JCO.2017.73.7916"},{"key":"141_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1517\/17425250902800153","volume":"5","author":"VH Phan","year":"2009","unstructured":"Phan, V. H. et al. Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert. Opin. Drug. Metab. Toxicol. 5, 243\u2013257 (2009).","journal-title":"Expert. Opin. Drug. Metab. Toxicol."},{"key":"141_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.55","volume":"4","author":"J Lu","year":"2014","unstructured":"Lu, J. et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 4, e239 (2014).","journal-title":"Blood Cancer J."},{"key":"141_CR37","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1182\/blood-2014-05-573733","volume":"124","author":"MV Mateos","year":"2014","unstructured":"Mateos, M. V. et al. GEM2005 trial update comparing VMP\/VTP as induction in elderly multiple myeloma patients: do we still need alkylators? Blood 124, 1887\u20131893 (2014).","journal-title":"Blood"},{"key":"141_CR38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong, K. et al. Multiple myeloma: patient outcomes in real-world practice. Br. J. Haematol. 175, 252\u2013264 (2016).","journal-title":"Br. J. Haematol."},{"key":"141_CR39","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1200\/JCO.2009.25.2114","volume":"28","author":"H Ludwig","year":"2010","unstructured":"Ludwig, H. et al. Survival and years of life lost in different age cohorts of patients with multiple myeloma. J. Clin. Oncol. 28, 1599\u20131605 (2010).","journal-title":"J. Clin. Oncol."},{"key":"141_CR40","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s00228-017-2227-1","volume":"73","author":"BE Oortgiesen","year":"2017","unstructured":"Oortgiesen, B. E. et al. The role of initial clinical presentation, comorbidity and treatment in multiple myeloma patients on survival: a detailed population-based cohort study. Eur. J. Clin. Pharmacol. 73, 771\u2013778 (2017).","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"141_CR41","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt, M. et al. A concise revised myeloma comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102, 910\u2013921 (2017).","journal-title":"Haematologica"},{"key":"141_CR42","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","volume":"101","author":"M Engelhardt","year":"2016","unstructured":"Engelhardt, M. et al. Geriatric assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other common comorbidity scores. Haematologica 101, 1110\u20131119 (2016).","journal-title":"Haematologica"},{"key":"141_CR43","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo, A. et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood 125, 2068\u20132074 (2015).","journal-title":"Blood"},{"key":"141_CR44","first-page":"924","volume":"27","author":"S Lonial","year":"2013","unstructured":"Lonial, S. & Kaufman, J. L. Non-secretory myeloma: a clinician\u2019s guide. Oncology 27, 924\u2013928 (2013). 930.","journal-title":"Oncology"},{"key":"141_CR45","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/cei.12011","volume":"171","author":"SH Murng","year":"2013","unstructured":"Murng, S. H. et al. Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma. Clin. Exp. Immunol. 171, 201\u2013209 (2013).","journal-title":"Clin. Exp. Immunol."},{"key":"141_CR46","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle, R. A. et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin. Proc. 78, 21\u201333 (2003).","journal-title":"Mayo Clin. Proc."},{"key":"141_CR47","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.3109\/10428194.2015.1124994","volume":"57","author":"P Tacchetti","year":"2016","unstructured":"Tacchetti, P. et al. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens. Leuk. Lymphoma 57, 2058\u20132064 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"141_CR48","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.jgo.2017.09.007","volume":"9","author":"P Hari","year":"2018","unstructured":"Hari, P. et al. The impact of age and comorbidities on practice patterns and outcomes in patients with relapsed\/refractory multiple myeloma in the era of novel therapies. J. Geriatr. Oncol. 9, 138\u2013144 (2018).","journal-title":"J. Geriatr. Oncol."},{"key":"141_CR49","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld, P. et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood 127, 2955\u20132962 (2016).","journal-title":"Blood"},{"key":"141_CR50","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1080\/10428194.2016.1260126","volume":"58","author":"GL Shah","year":"2017","unstructured":"Shah, G. L. et al. Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. Leuk. Lymphoma 58, 1823\u20131831 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"141_CR51","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/leu.2013.225","volume":"28","author":"B Hebraud","year":"2014","unstructured":"Hebraud, B. et al. Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients. Leukemia 28, 675\u2013679 (2014).","journal-title":"Leukemia"},{"key":"141_CR52","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","volume":"128","author":"H Avet-Loiseau","year":"2016","unstructured":"Avet-Loiseau, H. et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood 128, 1174\u20131180 (2016).","journal-title":"Blood"},{"key":"141_CR53","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.clml.2014.12.002","volume":"15","author":"RM Rifkin","year":"2015","unstructured":"Rifkin, R. M. et al. Connect MM Registry: The Importance of Establishing Baseline Disease Characteristics. Clin. Lymphoma Myeloma Leuk. 15, 368\u2013376 (2015).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"141_CR54","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00277-013-1841-y","volume":"93","author":"E Katodritou","year":"2014","unstructured":"Katodritou, E. et al. \u201cReal-world\u201d data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group. Ann. Hematol. 93, 129\u2013139 (2014).","journal-title":"Ann. Hematol."},{"key":"141_CR55","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1002\/ajh.24131","volume":"90","author":"N Majithia","year":"2015","unstructured":"Majithia, N. et al. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Am. J. Hematol. 90, 981\u2013985 (2015).","journal-title":"Am. J. Hematol."},{"key":"141_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.31","volume":"7","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 7, e554 (2017).","journal-title":"Blood Cancer J."},{"key":"141_CR57","doi-asserted-by":"publisher","first-page":"867","DOI":"10.4065\/79.7.867","volume":"79","author":"SK Kumar","year":"2004","unstructured":"Kumar, S. K. et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin. Proc. 79, 867\u2013874 (2004).","journal-title":"Mayo Clin. Proc."},{"key":"141_CR58","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1200\/JCO.2006.09.6198","volume":"25","author":"B Freidlin","year":"2007","unstructured":"Freidlin, B. et al. Proposal for the use of progression-free survival in unblinded randomized trials. J. Clin. Oncol. 25, 2122\u20132126 (2007).","journal-title":"J. Clin. Oncol."},{"key":"141_CR59","volume-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims","author":"Center for Drug Evaluation and Research.","year":"2009","unstructured":"Center for Drug Evaluation and Research. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. (United States Food and Drug Administration, Silver Spring, 2009)."},{"key":"141_CR60","doi-asserted-by":"publisher","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","volume":"117","author":"SV Rajkumar","year":"2011","unstructured":"Rajkumar, S. V. et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 117, 4691\u20134695 (2011).","journal-title":"Blood"},{"key":"141_CR61","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"141_CR62","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade, J. et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br. J. Haematol. 102, 1115\u20131123 (1998).","journal-title":"Br. J. Haematol."},{"key":"141_CR63","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie, B. G. et al. International uniform response criteria for multiple myeloma. Leukemia 20, 1467\u20131473 (2006).","journal-title":"Leukemia"},{"key":"141_CR64","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/jnci\/djn012","volume":"100","author":"PG Richardson","year":"2008","unstructured":"Richardson, P. G., Niesvizky, R., Anderson, K. C. & Blade, J. Re: When you look matters: the effect of assessment schedule on progression-free survival. J. Natl Cancer Inst. 100, 373 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"141_CR65","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/leu.2013.220","volume":"28","author":"S Lonial","year":"2014","unstructured":"Lonial, S. & Anderson, K. C. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia 28, 258\u2013268 (2014).","journal-title":"Leukemia"},{"key":"141_CR66","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","volume":"11","author":"SV Rajkumar","year":"2010","unstructured":"Rajkumar, S. V. et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 11, 29\u201337 (2010).","journal-title":"Lancet Oncol."},{"key":"141_CR67","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2016.176","volume":"31","author":"R Hajek","year":"2017","unstructured":"Hajek, R. et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia 31, 107\u2013114 (2017).","journal-title":"Leukemia"},{"key":"141_CR68","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1016\/j.clml.2017.03.045","volume":"17","author":"T Facon","year":"2017","unstructured":"Facon, T. et al. Phase 3 Study (CLARION) of Carfilzomib, Melphalan, Prednisone (KMP) v Bortezomib, Melphalan, Prednisone (VMP) in Newly Diagnosed Multiple Myeloma (NDMM). Clin. Lymphoma Myeloma Leuk. 17, e26\u2013e27 (2017).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"141_CR69","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","volume":"113","author":"H Ludwig","year":"2009","unstructured":"Ludwig, H. et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113, 3435\u20133442 (2009).","journal-title":"Blood"},{"key":"141_CR70","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/cncr.23546","volume":"113","author":"B Barlogie","year":"2008","unstructured":"Barlogie, B. et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 113, 355\u2013359 (2008).","journal-title":"Cancer"},{"key":"141_CR71","doi-asserted-by":"publisher","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","volume":"26","author":"JJ Lahuerta","year":"2008","unstructured":"Lahuerta, J. J. et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J. Clin. Oncol. 26, 5775\u20135782 (2008).","journal-title":"J. Clin. Oncol."},{"key":"141_CR72","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41375-018-0091-3","volume":"32","author":"L Garderet","year":"2018","unstructured":"Garderet, L. et al. Association between response kinetics and outcomes in relapsed\/refractory multiple myeloma: analysis from TOURMALINE-MM1. Leukemia 32, 2032\u20132036 (2018).","journal-title":"Leukemia"},{"key":"141_CR73","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","volume":"117","author":"F Gay","year":"2011","unstructured":"Gay, F. et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117, 3025\u20133031 (2011).","journal-title":"Blood"},{"key":"141_CR74","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","volume":"125","author":"AC Rawstron","year":"2015","unstructured":"Rawstron, A. C. et al. Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction. Blood 125, 1932\u20131935 (2015).","journal-title":"Blood"},{"key":"141_CR75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/ejh.12882","volume":"99","author":"LK Nielsen","year":"2017","unstructured":"Nielsen, L. K., Jarden, M., Andersen, C. L., Frederiksen, H. & Abildgaard, N. A systematic review of health-related quality of life in longitudinal studies of myeloma patients. Eur. J. Haematol. 99, 3\u201317 (2017).","journal-title":"Eur. J. Haematol."},{"key":"141_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2410-2","volume":"16","author":"C Ramsenthaler","year":"2016","unstructured":"Ramsenthaler, C. et al. The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. Bmc. Cancer 16, 427 (2016).","journal-title":"Bmc. Cancer"},{"key":"141_CR77","doi-asserted-by":"publisher","first-page":"3921","DOI":"10.1200\/JCO.2016.66.9648","volume":"34","author":"AK Stewart","year":"2016","unstructured":"Stewart, A. K. et al. Health-Related Quality of Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma. J. Clin. Oncol 34, 3921\u20133930 (2016).","journal-title":"J. Clin. Oncol"},{"key":"141_CR78","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.clml.2015.05.007","volume":"15","author":"K Weisel","year":"2015","unstructured":"Weisel, K. et al. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed\/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. Clin. Lymphoma Myeloma Leuk. 15, 519\u2013530 (2015).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"141_CR79","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/ajh.25134","volume":"93","author":"X Leleu","year":"2018","unstructured":"Leleu, X. et al. Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed\/refractory multiple myeloma. Am. J. Hematol 93, 985\u2013993 (2018).","journal-title":"Am. J. Hematol"},{"key":"141_CR80","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jpainsymman.2011.06.019","volume":"43","author":"LI Wagner","year":"2012","unstructured":"Wagner, L. I. et al. Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction. J. Pain. Symptom Manag. 43, 1094\u20131104 (2012).","journal-title":"J. Pain. Symptom Manag."},{"key":"141_CR81","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/ejh.12012","volume":"89","author":"TR Osborne","year":"2012","unstructured":"Osborne, T. R. et al. What issues matter most to people with multiple myeloma and how well are we measuring them? A systematic review of quality of life tools. Eur. J. Haematol. 89, 437\u2013457 (2012).","journal-title":"Eur. J. Haematol."},{"key":"141_CR82","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjh.14514","volume":"176","author":"JA Snowden","year":"2017","unstructured":"Snowden, J. A. et al. Guidelines for screening and management of late and long-term consequences of myeloma and its treatment. Br. J. Haematol. 176, 888\u2013907 (2017).","journal-title":"Br. J. Haematol."},{"key":"141_CR83","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/10428194.2016.1177772","volume":"58","author":"K Weisel","year":"2017","unstructured":"Weisel, K. et al. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Leuk. Lymphoma 58, 153\u2013161 (2017).","journal-title":"Leuk. Lymphoma"},{"key":"141_CR84","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.clml.2017.12.012","volume":"18","author":"P Hari","year":"2018","unstructured":"Hari, P. et al. Prolonged Duration of Therapy Is Associated With Improved Survival in Patients Treated for Relapsed\/Refractory Multiple Myeloma in Routine Clinical Care in the United States. Clin. Lymphoma Myeloma Leuk. 18, 152\u2013160 (2018).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"141_CR85","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman, R. E. et al. Real-World Evidence - What Is It and What Can It Tell Us? N. Engl. J. Med. 375, 2293\u20132297 (2016).","journal-title":"N. Engl. J. Med."},{"issue":"15 suppl","key":"141_CR86","doi-asserted-by":"crossref","first-page":"e17586","DOI":"10.1200\/jco.2013.31.15_suppl.e17586","volume":"31","author":"AJ Combest","year":"2013","unstructured":"Combest, A. J., Reitsma, D. J., Moseley, A., Steele, S. D. & Bonneterre, M.-E. A. Adult participation in oncology clinical trials by indication, race, and age. J. Clin. Oncol. 31(15 suppl), e17586 (2013).","journal-title":"J. Clin. Oncol."},{"key":"141_CR87","unstructured":"Myeloma, U. K. Myeloma Patient Experience Report 2016. (Myeloma, UK, 2016)."},{"key":"141_CR88","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1038\/bjc.2013.725","volume":"110","author":"CM Booth","year":"2014","unstructured":"Booth, C. M. & Tannock, I. F. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br. J. Cancer 110, 551\u2013555 (2014).","journal-title":"Br. J. Cancer"},{"key":"141_CR89","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3816\/CLML.2010.n.120","volume":"11","author":"JF San-Miguel","year":"2011","unstructured":"San-Miguel, J. F. et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin. Lymphoma Myeloma Leuk. 11, 38\u201343 (2011).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"141_CR90","doi-asserted-by":"publisher","first-page":"99","DOI":"10.6004\/jnccn.2009.0009","volume":"7","author":"GH Lyman","year":"2009","unstructured":"Lyman, G. H. Impact of chemotherapy dose intensity on cancer patient outcomes. J. Natl Compr. Canc. Netw. 7, 99\u2013108 (2009).","journal-title":"J. Natl Compr. Canc. Netw."},{"key":"141_CR91","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/ejh.12876","volume":"99","author":"D Robinson Jr.","year":"2017","unstructured":"Robinson, D. Jr. et al. Economic Burden of Relapsed or Refractory Multiple Myeloma: Results from an International Trial. Eur. J. Haematol. 99, 119\u2013132 (2017).","journal-title":"Eur. J. Haematol."},{"key":"141_CR92","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","volume":"2","author":"SF Huntington","year":"2015","unstructured":"Huntington, S. F. et al. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. Lancet Haematol. 2, e408\u2013e416 (2015).","journal-title":"Lancet Haematol."},{"key":"141_CR93","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1007\/s00520-016-3363-3","volume":"24","author":"M Touati","year":"2016","unstructured":"Touati, M. et al. Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home. Support. Care Cancer 24, 5007\u20135014 (2016).","journal-title":"Support. Care Cancer"},{"key":"141_CR94","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1056\/NEJMra1510061","volume":"375","author":"DL Bhatt","year":"2016","unstructured":"Bhatt, D. L. & Mehta, C. Adaptive Designs for Clinical Trials. N. Engl. J. Med. 375, 65\u201374 (2016).","journal-title":"N. Engl. J. Med."},{"key":"141_CR95","unstructured":"Sridhara, R. Innovative adaptive trial designs. https:\/\/www.fda.gov\/downloads\/Drugs\/NewsEvents\/UCM464307.pdf (United States Food and Drug Administration, 2015)."},{"key":"141_CR96","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1200\/JCO.2017.76.5032","volume":"36","author":"DS Siegel","year":"2018","unstructured":"Siegel, D. S. et al. Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. J. Clin. Oncol 36, 728\u2013734 (2018).","journal-title":"J. Clin. Oncol"},{"key":"141_CR97","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 18, 1327\u20131337 (2017).","journal-title":"Lancet Oncol."},{"key":"141_CR98","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjh.14787","volume":"178","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Elotuzumab plus lenalidomide\/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br. J. Haematol. 178, 896\u2013905 (2017).","journal-title":"Br. J. Haematol."},{"key":"141_CR99","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood.V130.Suppl_1.739.739","volume":"130","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (RRMM): Updated Efficacy and Safety Analysis of Pollux. Blood 130, 739 (2017).","journal-title":"Blood"},{"key":"141_CR100","first-page":"1852","volume":"130","author":"S Lentzsch","year":"2017","unstructured":"Lentzsch, S. et al. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed\/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor. Blood 130, 1852 (2017).","journal-title":"Blood"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0141-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0141-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0141-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T06:39:11Z","timestamp":1671518351000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-018-0141-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,9]]},"references-count":100,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11]]}},"alternative-id":["141"],"URL":"https:\/\/doi.org\/10.1038\/s41408-018-0141-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,9]]},"assertion":[{"value":"10 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.G.R.: Jazz Pharmaceuticals: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Research Funding; Oncopeptides AB: Membership on an entity\u2019s Board of Directors or advisory committees; Takeda: Consultancy, Research Funding. J.S.M.: Celgene: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees; Bristol-Myers Squibb: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees; Takeda: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees; MSD: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees; Amgen: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees; Janssen: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees; Roche: Membership on an entity\u2019s Board of Directors or advisory committees; Sanofi: Consultancy, Membership on an entity\u2019s Board of Directors or advisory committees. P.M.: Novartis: Consultancy, Honoraria; Celgene, Janssen, Takeda, Novartis, Amgen, Roche: Membership on an entity\u2019s Board of Directors or advisory committees; Celgene: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Janssen: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Bristol-Myers Squibb: Consultancy, Honoraria; Millennium: Consultancy, Honoraria; Onyx Pharmaceutical: Consultancy, Honoraria. R.H.: Takeda: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Pharma MAR: Consultancy, Honoraria; BMS: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Membership on an entity\u2019s Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria. M.A.D.: Genesis Pharma: Research Funding; Novartis: Consultancy, Honoraria; Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology: Consultancy, Honoraria, Other: Advisory Committee: Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology. D.R., A.P., T.S.: Employment: Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. T.S.: Also affiliated with Department of Hematology, Charles University General Hospital Prague, Czech Republic. K.L.: Employment, previously Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, currently TESARO, Waltham, MA. S.K.K.: Skyline: Honoraria; Celgene, Millennium, BMS, Onyx, Janssen, Noxxon, AbbVie, Amgen, Merck, Oncopeptides, Skyline Diagnostics, Takeda: Consultancy; Celgene, Millennium\/Takeda, Onyx, AbbVie, Janssen, Sanofi, Novartis, Amgen, Genentech, Merck, Oncopeptides, Roche, Skyline Diagnostics: Research Funding. K.C.A.: Bristol-Myers Squibb: Membership on an entity\u2019s Board of Directors or advisory committees; Gilead Sciences: Membership on an entity\u2019s Board of Directors or advisory committees; MedImmune: Membership on an entity\u2019s Board of Directors or advisory committees; Oncopep: Other: scientific founder; Millennium Pharmaceuticals: Membership on an entity\u2019s Board of Directors or advisory committees; C4 Therapeutics: Other: scientific founder.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"109"}}